Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for japanese women with rare ovarian cancer: drug combo shows promise

NCT ID NCT06682572

Ongoing Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 11 times

Summary

This study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has come back after at least one round of platinum chemotherapy. The goal is to see if the drugs can shrink or control the tumors. Participants must have a specific KRAS gene mutation and measurable disease. This is not a cure, but aims to manage the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, 464-8681, Japan

  • Jikei University Hospital

    Minato, Tokyo, 105-0003, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, 830-0011, Japan

  • Mie University Hospital

    Tsu, Mie-ken, 514-8507, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

Conditions

Explore the condition pages connected to this study.

LOW GRADE SEROUS OVARIAN CANCER LOW-GRADE SEROUS OVARIAN CANCER OVARIAN CANCER